Armstrong Pharmaceuticals is the only manufacturer that has not transitioned from albuterol metered-dose inhalers using chlorofluorocarbon (CFC) propellants to hydrofluroalkane- (HFA) propelled albuterol inhalers, the FDA says. As of Dec. 31, only CFC-free inhalers may be marketed in the U.S. Some manufacturers, including GlaxoSmithKline (GSK) and Schering-Plough, initially expressed reservations about the Dec. 31 deadline. But most manufacturers have made the transition and have increased production to ensure an adequate supply of HFA inhalers.
Devices & Diagnostics Letter